Genmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Wall Street Zen

Genmab A/S (NASDAQ:GMAB) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Other equities analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and set a $39.00 target price on shares of Genmab A/S in a report on Wednesday, January 28th. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Truist Financial restated a “buy” rating and issued a $48.00 target price (down from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Finally, Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and an average price target of $39.25.

Genmab A/S Stock Performance

Shares of GMAB opened at $30.90 on Friday. The firm has a market cap of $19.85 billion, a PE ratio of 13.15, a PEG ratio of 18.18 and a beta of 0.90. The firm’s 50 day moving average price is $32.50 and its 200 day moving average price is $29.41. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $35.43.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC increased its position in Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after acquiring an additional 1,143 shares during the period. Brown Brothers Harriman & Co. grew its position in Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the last quarter. Founders Capital Management raised its position in shares of Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after buying an additional 400 shares during the last quarter. Community Bank N.A. bought a new stake in shares of Genmab A/S in the third quarter valued at about $47,000. Finally, Cromwell Holdings LLC grew its position in Genmab A/S by 136.3% during the third quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after buying an additional 883 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.